BH3:FRA
PTC Therapeutics, Inc.
€56.84
arrow_downward
-0.07%(-0.040) 1D
Nov 13, 10:00:00 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
€56.16
High
€56.84
Low
€56.16
Mkt. cap
5.30B
Volume
0.00
52-wk high
€77.02
52-wk low
€51.64
No. of employees
991
Open
€56.16
High
€56.84
Low
€56.16
Mkt. cap
5.30B
Volume
0.00
52-wk high
€77.02
52-wk low
€51.64
No. of employees
991
News stories
From web sources and news partners
BigGo Finance
·
16 hours ago
Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks
The Motley Fool
·
11 hours ago
This Dividend King Yields 5 Times the S&P 500. Is It a Buy Now?
TradingKey
·
1 day ago
S&P 500 Forecast: Index Poised to Retest Record High in November After 500-Point Pullback, Biggest Daily Gain in Nearly Seven Months
StoneX
·
2 days ago
S&P 500, Nasdaq 100 Claw Back But NVDA Cloud Looms Overhead
Profile
PTC Therapeutics, Inc. is an U.S.-based pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapies that alter gene expression via post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorHealth Care
IndustryBiotechnology
Websiteptcbio.com